<?xml version="1.0" encoding="UTF-8"?>
<search_results count="42">
  <query>harvoni</query>
  <study rank="1">
    <title>Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Harvoni</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02591277</url>
  </study>
  <study rank="2">
    <title>Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Harvoni (Fixed dose combination ledipasvir/sofosbuvir)</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02347345</url>
  </study>
  <study rank="3">
    <title>Effect of Harvoni on Proteinuria and Estimated Glomerular Filtration Rate (eGFR) in Hepatitis C (HCV) Associated Chronic Kidney Disease (CKD)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir/Ledipasvir FDC</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02503735</url>
  </study>
  <study rank="4">
    <title>Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Cirrhosis, Decompensated</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/Sofosbuvir</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02597166</url>
  </study>
  <study rank="5">
    <title>Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre or Post Liver Transplant</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Harvoni</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02533934</url>
  </study>
  <study rank="6">
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Subjects With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01987453</url>
  </study>
  <study rank="7">
    <title>Switching Regimen in Treating Cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 12 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 12 wk</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02583685</url>
  </study>
  <study rank="8">
    <title>Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>PT-NANBH</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">8 weeks SOF/LED</intervention>
      <intervention type="Drug">12 weeks SOF/LED</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02480166</url>
  </study>
  <study rank="9">
    <title>Study to Assess Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir and Sofosbuvir Combined</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02339038</url>
  </study>
  <study rank="10">
    <title>CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Usual care plus peer-mentors</intervention>
      <intervention type="Other">Usual care plus incentives</intervention>
      <intervention type="Other">Usual Care</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02402218</url>
  </study>
  <study rank="11">
    <title>12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-1 Infection</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02605304</url>
  </study>
  <study rank="12">
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Treatment of Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/Sofosbuvir FDC</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02480387</url>
  </study>
  <study rank="13">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02613871</url>
  </study>
  <study rank="14">
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02600351</url>
  </study>
  <study rank="15">
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+DCV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02576314</url>
  </study>
  <study rank="16">
    <title>DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>HBV Coinfection</condition>
      <condition>Hepatitis B Reactivation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/Sofosbuvir</intervention>
      <intervention type="Drug">Sofosbuvir and Daclatasvir</intervention>
      <intervention type="Drug">Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">Tenofovir disoproxil</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02555943</url>
  </study>
  <study rank="17">
    <title>A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir (SOF)</intervention>
      <intervention type="Drug">Ledipasvir/Sofosbuvir (LDV/SOF)</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02510300</url>
  </study>
  <study rank="18">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02487030</url>
  </study>
  <study rank="19">
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+RBV</intervention>
      <intervention type="Drug">SOF+DCV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02482077</url>
  </study>
  <study rank="20">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection.</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02472886</url>
  </study>
  <study rank="21">
    <title>Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF+ASV</intervention>
      <intervention type="Drug">SOF+DCV+SMV</intervention>
      <intervention type="Drug">SOF+DCV+ASV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02470858</url>
  </study>
  <study rank="22">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection With HIV Co-Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02457611</url>
  </study>
  <study rank="23">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02413593</url>
  </study>
  <study rank="24">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02350569</url>
  </study>
  <study rank="25">
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02301936</url>
  </study>
  <study rank="26">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02251717</url>
  </study>
  <study rank="27">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">Placebo to match LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02249182</url>
  </study>
  <study rank="28">
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">VDV</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02226549</url>
  </study>
  <study rank="29">
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02120300</url>
  </study>
  <study rank="30">
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Genotype 4 HCV</condition>
      <condition>Chronic Genotype 5 HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02081079</url>
  </study>
  <study rank="31">
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02073656</url>
  </study>
  <study rank="32">
    <title>Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match LDV/SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01965535</url>
  </study>
  <study rank="33">
    <title>Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF 100 mg</intervention>
      <intervention type="Drug">SOF 400 mg</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01958281</url>
  </study>
  <study rank="34">
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01938430</url>
  </study>
  <study rank="35">
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01924949</url>
  </study>
  <study rank="36">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01851330</url>
  </study>
  <study rank="37">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01768286</url>
  </study>
  <study rank="38">
    <title>Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01726517</url>
  </study>
  <study rank="39">
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01701401</url>
  </study>
  <study rank="40">
    <title>Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">LDV</intervention>
      <intervention type="Drug">GS-9669</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT01260350</url>
  </study>
  <study rank="41">
    <title>Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Elbasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <url>https://ClinicalTrials.gov/show/NCT02601573</url>
  </study>
  <study rank="42">
    <title>The Patient-Reported Outcomes Project of HCV-TARGET</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Diseases</condition>
    </conditions>
    <interventions/>
    <url>https://ClinicalTrials.gov/show/NCT02601820</url>
  </study>
</search_results>
